Moderna and Merck melanoma vaccine reportedly lowered recurrence risk by 42% in trial

STAT reports a 42% lower melanoma recurrence risk with Moderna and Merck's personalized mRNA vaccine than with standard treatment in a large trial. The therapy targets mutations unique to each tumor, and STAT says the data met key endpoints. Its opening report does not identify the exact comparator arm. Reporter Adam Feuerstein announced an ESMO embargo lift after a breach; earlier posts about a leak and a share drop were unverified claims.